Plexus Corp. (PLXS)

Executive Summary / Key Takeaways

• Plexus is executing a technology-enabled margin expansion story in the electronic manufacturing services industry, using AI and automation to drive structural cost reductions.
• Record quarterly wins in Aerospace & Defense ($220M annualized) and robust Healthcare growth (+24.6% YoY) demonstrate successful diversification into high-value, regulated markets that command pricing power.
• The company maintains disciplined capital allocation with a $100M free cash flow target for FY2026, $63M remaining on share repurchases, and a net cash position, while ROIC of 13.2% exceeds WACC by 420 basis points.
• New Malaysia facility's rapid path to profitability validates management's capacity expansion strategy and supports the high end of 9-12% revenue growth guidance.
• The central risk is execution: customer concentration amplifies volatility, new program ramps demand working capital (inventory days up 6 days in Q1), and larger competitors like Jabil (JBL) and Celestica (CLS) could pressure industrial/commercial margins.

Setting the Scene: The Mid-Tier EMS Player With a Different Playbook

Plexus Corp., founded in 1979 and headquartered in Neenah, Wisconsin, operates in the $650 billion global electronic manufacturing services industry. The company generates revenue by providing end-to-end solutions from product design through sustaining services, with engineering influencing approximately one-third of manufacturing revenue—a critical differentiator in a commoditized industry. Unlike EMS giants Jabil ($29.8B revenue) and Flex (FLEX) ($25.8B) that compete on scale across high-volume consumer electronics, Plexus targets high-mix, low-volume production in regulated sectors: Aerospace/Defense, Healthcare/Life Sciences, and Industrial/Commercial applications where compliance complexity creates natural barriers.

The EMS industry structure typically rewards scale, yet Plexus maintains gross margins of 9.98% and operating margins of 5.07%, both superior to larger peers like Sanmina (SANM) (8.49% gross, 3.69% operating). This performance stems from a deliberate strategy to embed deeply in customers' product development cycles, making the company difficult to displace once designed into mission-critical systems. The industry faces secular tailwinds from reshoring, supply chain diversification, and increasing product complexity in regulated markets—trends that favor specialized providers over pure scale players. Plexus's global footprint of 27 facilities across Americas, APAC, and EMEA provides the geographic flexibility customers demand, while its recent capacity investments signal confidence in capturing share in these high-value niches.

Technology, Automation, and the Structural Margin Story

Plexus's technology investments transcend typical EMS automation, creating measurable productivity gains that directly support margin expansion. The company deployed AutoStore 3D cube warehouse automation achieving a 60% reduction in space utilization and 300% increase in pick rates, while each robot replaces 1.5 to 2 full-time equivalents with less than 12-month ROI. This converts fixed warehouse costs into variable efficiency gains, freeing floor space for revenue-generating production and reducing labor costs in a tight labor market. These improvements persist regardless of volume fluctuations, insulating margins during downturns while amplifying leverage during growth phases.

Beyond physical automation, Plexus applies AI to optimize standard work times on high-mix assembly lines and accelerate quoting processes—directly impacting revenue velocity and labor efficiency. Management reports over 30% daily usage of AI tools across all employees, combining enterprise-level data science initiatives with democratized tools that drive frontline productivity. This generates both top-line acceleration and bottom-line efficiency, creating a rare combination of growth and margin expansion. For investors, this translates to sustainable competitive advantage: while competitors like Jabil and Flex must invest billions in capacity to grow, Plexus extracts more output from existing assets, as evidenced by ROIC of 13.2% that exceeds its 9% WACC by 420 basis points.

The Engineering Solutions business, generating over $100M annually at margins double the manufacturing average, represents the company's most defensible moat. This service line influences one-third of manufacturing revenue and has achieved its third-largest qualified opportunities funnel in company history, with Aerospace & Defense engineering at an all-time high. The economic impact is clear: engineering-led engagements command premium pricing and create switching costs, as customers cannot easily replicate Plexus's design expertise and regulatory knowledge. This differentiation counters the scale advantages of larger competitors, allowing Plexus to win on value rather than price in markets where failure is not an option.

Financial Performance: Evidence of Strategy Working

Fiscal 2025 results validated the margin expansion thesis with 40 basis points of non-GAAP operating margin expansion and over 30% non-GAAP EPS growth, demonstrating that technology investments translate to earnings leverage. The company secured 141 manufacturing wins worth $941M in annualized revenue, alongside record engineering and sustaining services wins, proving diversification beyond traditional healthcare concentration. This shows Plexus can grow both the top line and profitability simultaneously—a rarity in EMS where growth typically requires margin sacrifice for capacity investment.

First quarter fiscal 2026 results reinforced this momentum with consolidated revenue of $1.07B, driven by AMER segment growth of 25.9% to $344.8M and EMEA expansion of 17.0% to $118.4M. The EMEA segment's income growth of 109% to $9.4M, driven by favorable customer mix, demonstrates the operating leverage inherent in Plexus's model when higher-margin programs ramp. APAC's modest 0.8% growth to $611.7M with slight income decline reflects customer disengagement and increased fixed costs, highlighting the risk of concentration in any single region or program. This geographic mix shift toward higher-margin regions supports margin targets, while APAC's softness serves as a reminder that growth is not linear.

Segment performance reveals the strategic pivot's effectiveness. Aerospace & Defense revenue grew 11.5% YoY to $177.9M, with Q1 2026 representing a record $220M in new program wins—nearly matching prior annual records. Healthcare/Life Sciences surged 24.6% YoY to $466M as inventory overhangs cleared and surgical/monitoring demand strengthened. Industrial declined 3.7% YoY to $425.9M, but management expects high single to low double-digit sequential growth in Q2 driven by semicap recovery . Plexus is successfully reallocating resources toward higher-value sectors while maintaining optionality in cyclical industrial markets, creating a more resilient earnings profile than pure-play industrial competitors.

Cash flow dynamics in Q1 2026 show the working capital demands of rapid growth, with operations consuming $16M and capex of $35M resulting in negative free cash flow of $50.6M. However, management reconfirmed the $100M fiscal 2026 free cash flow target, demonstrating confidence that inventory investments will convert to cash as programs ramp. The company ended the quarter in a net cash position with only $60M drawn on its $500M revolver, providing ample liquidity to fund growth. This shows Plexus can self-finance expansion without diluting shareholders, while the $22.4M in Q1 share repurchases signal management believes the stock offers better returns than alternative investments.

Outlook, Guidance, and Execution Risk

Management's guidance for fiscal 2026 reveals ambitious targets that hinge on execution of new program ramps. Revenue growth is now expected to meet or exceed the high end of the 9-12% range, with Q2 guidance of $1.11-1.15B representing 15% YoY growth at the midpoint. The non-GAAP operating margin target of 6% requires maintaining gross margins near 10% while leveraging SG&A, which declined as a percentage of revenue in Q1 despite absolute increases. This implies 50-70 bps of margin expansion from FY2025's 5.3% level, a significant move in a 9-10% gross margin business where operating leverage is hard-won.

The Malaysia facility's trajectory provides a microcosm of execution risk and reward. Opened in summer 2025, it was quickly brought to profitability due to strategic campus design and rapid onboarding of significant new business, with expectations to approach corporate average margins in the back half of fiscal 2026. The facility's $500M revenue potential, expandable to $1B, represents 12-25% of current revenue base, making its ramp critical to growth targets. Facility start-ups typically drag margins for 12-18 months in EMS; Plexus's rapid profitability demonstrates superior site selection and customer demand, but any delays would pressure both revenue and margin guidance.

Key assumptions underpinning guidance include continued strength in Aerospace & Defense program ramps, modest improvement in commercial aerospace, and early-stage semicap demand recovery. Healthcare's inventory overhang has largely cleared, with surgical and monitoring technology demand strengthening. The industrial sector's softness in test/measurement, heavy equipment, and energy is expected to be offset by semicap growth and new program ramps. If Boeing (BA) production accelerates or semicap enters a full cycle, Plexus could exceed already-raised targets, while the diversified portfolio provides downside protection against any single market collapse.

Competitive Context: Punching Above Its Weight

Plexus's competitive positioning reveals a deliberate choice to sacrifice scale for specialization, creating measurable advantages in targeted segments. Against Jabil's $29.8B revenue and 4.67% operating margin, Plexus's $4B scale and 5.07% margin demonstrate superior profitability per dollar of revenue, though Jabil's 59.7% ROE reflects superior asset turnover at scale. Jabil's 3.25 debt-to-equity ratio versus Plexus's 0.13 shows Plexus's conservative balance sheet provides strategic flexibility. Plexus competes on margin quality rather than volume, a sustainable strategy only if it can maintain pricing power in its niche markets.

Flex presents a more direct margin comparison with 5.67% operating margin and similar gross margin at 9.27%, but its $25.8B scale and 0.98 debt-to-equity ratio reflect a more aggressive growth strategy. Plexus's 12.63% ROE lags Flex's 16.85%, but its lower beta indicates less cyclical volatility—a meaningful advantage for long-term investors. Flex's heavy exposure to hyperscaler data center builds creates AI-driven growth but also customer concentration risk, while Plexus's diversified regulated markets provide stability. This implies Plexus trades growth potential for earnings quality, a reasonable exchange given EMS cyclicality.

Sanmina and Celestica represent the bifurcated paths Plexus could follow. Sanmina's 3.69% operating margin and 9.73% ROE show the challenges of mid-tier scale without differentiation, while Celestica's 8.71% operating margin and 40.49% ROE demonstrate the rewards of AI infrastructure exposure. Plexus sits between them: its 5.07% margin exceeds Sanmina's but trails Celestica's, while its regulated market focus provides more defensible moats than Sanmina's but less growth than Celestica's data center surge. Plexus must execute its technology-driven margin story flawlessly to avoid being squeezed between low-cost specialists and high-growth AI players.

Risks and Asymmetries: What Could Break the Thesis

Customer concentration represents the most material risk, with the top 10 customers comprising approximately 52% of revenue. In Q1 2026, both AMER and APAC segments cited customer disengagements as offsets to growth, demonstrating how single program losses can move the needle. Plexus's specialized capabilities, while creating stickiness, also limit the addressable market for any single customer—losing a major healthcare or aerospace client could create a revenue hole that takes quarters to fill. The risk is amplified against competitors like Jabil and Flex with more diversified customer bases, making Plexus more vulnerable to procurement shifts.

Execution risk on new facility ramps and working capital management presents near-term margin pressure. The 6-day increase in cash cycle to 69 days, driven by inventory builds for anticipated revenue, shows management is betting on successful program launches. If ramps are delayed, inventory could become a drag on returns, while fixed costs at underutilized facilities would compress margins. This risk is mitigated by customer deposits of $386.5M to support inventory, but the working capital intensity of EMS means execution missteps quickly translate to cash flow misses.

Tariff uncertainty and global minimum tax implementation create external cost pressures. Management's proactive approach—passing costs to customers, achieving 80% USMCA compliance in Mexico, and modeling product movements—demonstrates sophistication, but the 16-18% effective tax rate guidance reflects structural headwinds from global tax harmonization. This caps after-tax earnings growth even if pre-tax margins expand, and competitors with different geographic footprints may face lower tax burdens. Plexus's operational excellence must continuously outrun regulatory cost increases just to maintain current profitability levels.

Valuation Context: Pricing in Execution Excellence

At $202.79 per share, Plexus trades at 31.5x trailing earnings and 1.32x sales, valuation multiples that sit squarely in the middle of its peer group (JBL: 35.8x P/E, FLEX: 29.2x, SANM: 31.4x, CLS: 40.1x). The enterprise value of $5.38B represents 1.30x revenue and 18.7x EBITDA, reflecting a premium for profitability over pure scale plays like Sanmina (0.87x EV/Revenue) but a discount to high-growth Celestica (2.69x). This positioning suggests the market has fairly priced Plexus's current earnings power, leaving limited margin of safety but also no obvious overvaluation if the company hits its targets.

The price-to-free-cash-flow ratio of 71.2x appears elevated but reflects the temporary working capital investment phase; management's $100M FCF target for FY2026 would improve this to approximately 35x if achieved. More telling is the return on invested capital of 13.2% versus a 9% WACC, creating 420 basis points of economic value added that compounds over time. With debt-to-equity of just 0.13 and $440M available on its revolver, Plexus has untapped financial leverage to accelerate returns if management chooses to optimize the balance sheet. The valuation implies investors must believe in both the margin expansion story and management's ability to deploy capital efficiently—failure on either front would warrant a multiple compression toward Sanmina's levels.

Conclusion: A Quality Compounders' Test in a Cyclical Industry

Plexus has engineered a compelling investment thesis around technology-enabled margin expansion in an industry where most players compete solely on scale. The company's ability to generate 13.2% ROIC while maintaining net cash, grow EPS over 30% while expanding margins, and win record aerospace/defense programs demonstrates operational excellence that transcends its mid-tier size. The rapid profitability of new facilities, quantified automation benefits, and disciplined capital allocation create a story of quality compounding that justifies its market-average valuation multiples.

The investment case hinges on two variables: successful ramp of the Malaysia facility to support revenue growth approaching the high end of 9-12%, and sustained momentum in high-margin sectors to offset industrial softness. If Plexus executes, the combination of margin expansion, capital return, and ROIC improvement could drive mid-teens total returns even without multiple expansion. However, customer concentration risk and the working capital intensity of program ramps create downside asymmetry—execution missteps would likely result in both earnings misses and valuation compression toward lower-margin peers. For investors willing to underwrite management's track record, Plexus offers a rare combination of growth, quality, and capital discipline in a traditionally challenging sector.